bf/NASDAQ:ELEV_icon.jpeg

NASDAQ:ELEV

Elevation Oncology, Inc.

  • Stock

0.34

−8.48%

−0.02

USD last updated 13/08 01:59:42

Last Close

0.36

22/07 22:24

Market Cap

144.25M

Beta: -

Volume Today

479.75K

Avg: 819.79K

PE Ratio

−2.16

PFCF: −1.98

OverviewFinancialsAPI

This will be loaded shortly.

Loading

This is also still loading.

This will be loaded shortly.

Loading

This is also still loading.

This will be loaded shortly.

Loading

This is also still loading.

    Description

    Elevation Oncology, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for the treatment of cancer in genomically defined patient populations in the United States. The company's lead program is the seribantumab, an anti-HER3 monoclonal antibody that is in Phase II CRESTONE trial for the treatment of advanced solid tumors harboring a neuregulin-...Show More

    Excel Tearsheet

    Earnings

    Earnings per Share (Estimate*)

    -5-4-3-2-12020-03-312021-06-252022-08-042023-11-022024-08-012025-04-30

    Revenue (Estimate*)

    0.000.000.010.010.012020-03-312021-06-252022-08-042023-11-022024-08-012025-04-30

    *Estimate based on analyst consensus